A study of a GLP-1 and GIP medicine, tirzepatide, in people with lung cancer.

Who can join: Adults 18+, have lung cancer.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 4 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor University of ChicagoDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 30

What this study is for

Primary condition: Lung Cancer.

Full scientific study title: Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib.

Who can join

Age18 and upSexAny

Adults 18+, have lung cancer. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Age ≥ 18 years
Receiving lorlatinib as first-line treatment for advanced NSCLC ALK-positive, already prescribed and administered by the patient's treating oncologist as standard of care at the time of study enrollment. This study does not initiate lorlatinib therapy or assign lorlatinib dosing; participants must already be receiving lorlatinib prior to enrollment

Key exclusion criteria

Known hypersensitivity to GLP-1 agonists.
Active, unstable psychiatric illness; current suicidal ideation
Severe organ dysfunction or systemic illness.
Anorexia nervosa
History of pancreatitis

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

Illinois1 site

University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois
Clinical Trials Intake855-702-8222cancerclinicaltrials@bsd.uchicago.edu

Follow this trial

We email you if NCT07782359 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Scheduled start: October 2026. Expected completion: June 2030. Last updated on ClinicalTrials.gov: August 24, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.